Circulating Tumor DNA Testing Supports Rapid Therapeutic Decision-Making in Metastatic Melanoma: A Case Report
Treatment of metastatic melanoma includes the option of targeted therapy in patients with driver BRAF mutations.BRAF-MEK inhibitor drugs improve survival in the approximately 50% of patients with melanoma that harbor BRAF mutations.As BRAF mutation detection in tissue often takes days to weeks, it is not always possible or timely to obtain BRAF sta